Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 349-359

  Thorlund, Kristian ^a   Druyts, Eric ^b   El Khoury, Antoine C ^c   Mills, Edward J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Boceprevir; Budget impact analysis; Hepatitis C; Telaprevir

Indexed keywords

BOCEPREVIR; HYDROXYZINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ARTICLE; BAYES THEOREM; BUDGET IMPACT ANALYSIS; COST BENEFIT ANALYSIS; DRUG COST; DRUG RESPONSE; DRUG WITHDRAWAL; HEPATITIS C; HIDDEN MARKOV MODEL; HUMAN; TREATMENT DURATION; UNCERTAINTY; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

EID: 84869828234     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S37205     Document Type: Article

References (18)

1. Cooper C, Druyts E, Thorlund K, et al. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1infection: an indirect comparison meta-analysis. Ther Clin Risk Manag. 2012;8:105-130.
2. Poordad F, Khungar V. Emerging therapeutic options in hepatitis C virus infection. Am J Manag Care. 2011;17 Suppl 4:S123-S130.
3. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8: 257-264.
4. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol. 2011;8:69-71.
5. Cooper C, Lester R, Thorlund K, et al. Direct-acting antiviral therapies for hepatitis C genotype 1infection: a multiple treatment comparison meta-analysis. QJM. 2012. In press.
6. Nelson D, Jensen D, Sulkowski M. HCV clinical management resource. 2011. Available from: img. medscape. com/article/746/388/HCV_746388. pdf. Accessed October 8, 2012.
7. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 Infection. N Engl J Med. 2011;364(13):1195-1206.
8. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1infection. N Engl J Med. 2011;364(13): 1207-1217.
9. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
10. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with PEGinterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1in Japan. J Hepatol. 2011;56(1):78-84.
11. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and PEGinterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-1850.
12. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with PEGinterferon and ribavirin for chronic HCV genotype 1infection. N Engl J Med. 2009;360(18):1827-1838.
13. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14): 1292-1303.
14. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428.
15. MIMS. MIMS: Prescription drug database and drug prescribing guide. 2012. Available at: http://www.mims.co.uk/.
16. Sherman K, Flamm S, Afdhal N, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-1024.
17. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12hours with ribavirin and PEGinterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology. 2011;140(2):459.
18. Druyts E, Mills E, Nachega J, O'Regan C, Cooper C. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with PEGinterferon alpha-2a or PEGinterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol. 2012;5:11-21.